Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
11 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweightHigh blood pressure
Impact GLP-1 Agonists Following Bariatric
Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar
📍 University of Missouri Hospital · Columbia, MO · Get directions →
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.
- Obesity / overweight
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Testing a weekly shot to see if it is practical and helps weight in some postmenopausal breast
📍 Weill Cornell Medicine · New York, NY · Get directions →
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health.
- Obesity / overweight
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Testing adding tirzepatide to ixekizumab for plaque psoriasis and weight issues
📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
- Obesity / overweight
GLP-1R Actions on Muscle and the Skeleton
Studying how GLP-1 weight loss affects muscles and bones in people with obesity
📍 Pennington Biomedical Research Center · Baton Rouge, LA · Get directions →
The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.
- Obesity / overweight
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
Testing how weight-loss lifestyle changes affect metabolism in teens with obesity, with or without
📍 McMaster University · Hamilton, Ontario · Get directions →
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity. Behavioural lifestyle intervention with and without a pharmacological intervention - semaglutide- will be studied.
- Obesity / overweight
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Testing tirzepatide for hot flashes in post-menopausal women with obesity
📍 Mayo Clinic in Florida · Jacksonville, FL · Get directions →
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
- Obesity / overweight
2024 Tirzepatide-Bariatric Surgery
Testing whether taking tirzepatide before bariatric surgery helps outcomes for people with obesity
📍 University of Kentucky · Lexington, KY · Get directions →
This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity.
- Obesity / overweight
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
Testing oral semaglutide plus psoriasis skin creams to see effects on symptoms and inflammation
📍 Hospital Universitario Dr. José E. González · Monterrey, N.L. · Get directions →
This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks.
- Type 2 diabetesHeart / cardiovascular disease
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Testing tirzepatide to see if it slows plaque buildup in heart arteries in people with type 2
📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
- Obesity / overweight
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Testing whether adding tirzepatide to ixekizumab helps people with psoriatic arthritis and obesity
📍 AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale · Avondale, AZ · +39 more US sites · Get directions →
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
- Obesity / overweight
Tirzepatide in PWS, HO and GNSO
Testing a weight loss medication in young adults with Prader-Willi or hypothalamic obesity
📍 Children's Minnesota · Saint Paul, MN · +2 more US sites · Get directions →
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.